Earnings Ahead

NBIX - Neurocrine Biosciences Inc.

95.56 1.54 1.64

Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc.

About

Profile

Neurocrine’s management team participates in industry conferences providing presentations on company updates and progress on research and development activities. The company conducts webcasts and conference calls for these conferences and provides finan


Headquarters

San Diego, California, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

NBIX



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Neurocrine Biosciences Non-GAAP EPS of $1.54 beats by $0.03, revenue of $515.2M misses by $3.19M
  • Neurocrine Biosciences Q4 2023 Earnings Preview
  • Big Pharma earnings season in spotlight amid positive sentiment
  • Goldman says these stocks with weak pricing power can outperform
  • Biogen, Neurocrine, and more are Bairds top picks for biotech in 2024
  • Bristol-Karuna deal: What other biotechs might be in M&A crosshairs?
  • Top overweight stocks with high growth and low volume - MS
  • Citi starts Neurocrine at neutral, sees stock as fairly valued
  • Neurocrine gets FDA breakthrough therapy status for crinecerfont
  • The most crowded pharma longs and shorts, according to UBS
  • Neurocrine Biosciences executive discloses sale of over 10K shares
  • Neurocrine settles all patent disputes related to movement disorder therapy
  • Neurocrine reports Phase 2 study failures for two drug candidates
  • Neurocrine Biosciences Non-GAAP EPS of $1.54 beats by $0.21, revenue of $498.8M beats by $19.77M
  • Neurocrine Biosciences Q3 2023 Earnings Preview
  • Neurocrine says new Ingrezza version is under FDA review
  • Neurocrine gains after Phase 3 win for genetic disorder drug
  • Neurocrine releases new data on Ingrezza for Huntington's disease chorea
  • Neurocrine nabs FDA label expansion for Ingrezza
  • Neurocrine Biosciences Non-GAAP EPS of $1.25 beats by $0.13, revenue of $452.7M beats by $4.72M

Earnings History

Date EPS / Forecast Revenue / Forecast
February 11, 2022 -0.08 / 0.671 312M / 317.93M
November 1, 2021 0.23 / 0.5568 296M / 297.83M
August 3, 2021 0.43 / 0.5019 288.9M / 273.19M Beat!
May 5, 2021 0.33 / 0.5276 236.6M / 250.67M
February 4, 2021 3.58 / 0.6014 247.9M / 260.45M
November 9, 2020 -0.62 / -0.0194 258.5M / 282.7M
August 3, 2020 0.81 / 0.61 302.4M / 261.31M Beat!
May 6, 2020 0.39 / 0.54 237.1M / 226.53M Beat!
February 4, 2020 0.35 / 0.78 244.1M / 231.54M Beat!
November 4, 2019 0.56 / 0.66 222.09M / 211.97M Beat!
July 29, 2019 0.54 / 0.19 183.58M / 161.79M Beat!
April 29, 2019 -1.12 / -0.78 138.4M / 136.76M Beat!
February 5, 2019 0.19 / 0.18 131.49M / 132.34M
Date Price Open High Low Vol Change
May 17 142.29 141.97
142.86
140.51
642K 0.27%
May 16 141.91 141.17
142.22
140.17
671K -0.06%
May 15 142 138.9
142.16
138.9
685K 2.54%
May 14 138.48 137.12
138.73
134.81
637K 1.71%
May 13 136.15 138
138.56
135.24
696K -0.4%
 
May 10 136.7 140
141
136.11
679K -2.12%
May 9 139.66 139.36
140.55
138.95
479K 0.46%
May 8 139.02 143.5
143.54
138.15
654K -2.91%
May 7 143.19 142.03
143.85
140.91
667K 1.04%
May 6 141.71 140.55
143.52
140.55
391K 0.71%
May 3 140.71 140.9
141.88
139.23
615K 0.63%
May 2 139.83 143.79
144.09
139.63
874K -2.24%
May 1 143.03 140.18
145.22
136.01
1.6M 3.99%
Apr 30 137.54 138.07
140.47
137.34
965K -0.97%
Apr 29 138.89 136.05
139.37
136.05
682K 2.13%
Apr 26 135.99 137.47
138.63
135.17
709K -1.28%
Apr 25 137.76 139.37
139.37
136.06
706K -0.87%
Apr 24 138.97 140.89
144.7
138.01
883K -0.8%
Apr 23 140.09 141
145
139.22
1.6M 4.81%
Apr 22 133.66 132.48
134.18
131.79
567K 1.26%
Apr 19 132 132.65
133.65
130.13
556K -0.41%
Apr 18 132.54 133.23
134.2
131
549K -0.52%
Apr 17 133.23 133.11
134.44
131.36
571K 0.18%
Apr 16 132.99 131.78
135.18
131.49
1.0M 0.95%
Apr 15 131.74 134.97
137
131.52
755K -2.17%
Apr 12 134.66 136.22
137.78
134.63
577K -0.93%
Apr 11 135.93 138.03
138.67
135.28
809K -1.56%
Apr 10 138.09 138.45
140.54
137.09
639K -0.61%
Apr 9 138.94 140.07
141.45
138
599K -0.36%
Apr 8 139.44 138.03
139.68
137.72
616K 0.37%
Apr 5 138.92 137.43
139.75
136.03
459K 0.95%
Apr 4 137.61 138.17
140.43
136.74
1.0M 0.01%
Apr 3 137.59 137.72
140.18
137.36
614K -0.11%
Apr 2 137.74 140.61
140.61
136.12
914K -2.57%
Apr 1 141.38 137.3
141.75
136.85
979K 2.51%
Mar 28 137.92 137.83
138.72
135.97
1.2M 0.07%
Mar 27 137.83 141.38
141.73
133.43
1.2M -2.36%
Mar 26 141.16 141.43
142.31
139.94
595K 0.65%
Mar 25 140.25 141.5
142.08
138.85
535K -0.83%
Mar 22 141.43 145.31
145.42
137.35
938K -1.61%
Mar 21 143.74 140.05
148.37
139.31
2.5M 2.20%
Mar 20 140.65 140.75
141.65
137.14
653K -0.16%
Mar 19 140.87 140.84
141.06
138.32
755K 1.03%
Mar 18 139.44 139.25
141.82
138.57
641K 0.24%
Mar 15 139.1 138.67
142.15
138.67
1.7M -0.04%
Mar 14 139.16 141.8
142.5
137.83
1.2M -1.86%
Mar 13 141.8 138.73
141.91
138.32
1.1M 2.95%
Mar 12 137.74 138.64
139.98
137.66
638K -0.63%
Mar 11 138.61 139.22
140.25
137.31
617K -0.44%
Mar 8 139.22 136.27
140.33
136.27
999K 2.87%
Mar 7 135.33 132.93
135.6
132.62
728K 2.33%
Mar 6 132.25 133.77
134.67
131.65
623K -1.06%
Mar 5 133.67 133.39
135.15
132.12
878K 0.41%
Mar 4 133.12 131.55
134.27
130.98
963K 1.39%
Mar 1 131.3 131.65
132.64
129.15
1.3M 0.69%
Feb 29 130.4 135.51
136.1
130.04
1.7M -3.16%
Feb 28 134.66 136
136.03
133.82
808K -1.01%
Feb 27 136.03 135.12
136.55
134.52
818K 0.33%
Feb 26 135.58 134.25
136.2
133.17
777K 1.04%
Feb 23 134.18 133.87
134.65
132.73
542K 0%